Janux Therapeutics Commences Underwritten Public Offering Of $300M Of Shares Of Its Common Stock
Janux Therapeutics Commences Underwritten Public Offering Of $300M Of Shares Of Its Common Stock
Janux Therapeutics開始其普通股30000萬美元的認購股票的公開發行。
In addition, Janux expects to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions.
此外,Janux預計將在公募發售價的基礎上,給予承銷商一個爲期30天的選項,以購買額外價值4500萬美元的普通股,扣除承銷折扣和佣金。
The Company intends to use the net proceeds from the offering to advance clinical development of its internal product pipeline and for general corporate purposes.
公司計劃利用此次募資的淨收益推動其內部產品管線的臨床開發以及一般企業用途。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。